JP6490574B2 - 不溶性フィブリンに対する抗体 - Google Patents

不溶性フィブリンに対する抗体 Download PDF

Info

Publication number
JP6490574B2
JP6490574B2 JP2015503025A JP2015503025A JP6490574B2 JP 6490574 B2 JP6490574 B2 JP 6490574B2 JP 2015503025 A JP2015503025 A JP 2015503025A JP 2015503025 A JP2015503025 A JP 2015503025A JP 6490574 B2 JP6490574 B2 JP 6490574B2
Authority
JP
Japan
Prior art keywords
antibody
fibrinogen
fibrin
amino acid
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015503025A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2014133093A1 (ja
Inventor
保広 松村
保広 松村
正浩 安永
正浩 安永
洋平 久田
洋平 久田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Centre Japan
Original Assignee
National Cancer Centre Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Centre Japan filed Critical National Cancer Centre Japan
Publication of JPWO2014133093A1 publication Critical patent/JPWO2014133093A1/ja
Application granted granted Critical
Publication of JP6490574B2 publication Critical patent/JP6490574B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015503025A 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体 Active JP6490574B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013039625 2013-02-28
JP2013039625 2013-02-28
PCT/JP2014/054925 WO2014133093A1 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018137861A Division JP7012360B2 (ja) 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体

Publications (2)

Publication Number Publication Date
JPWO2014133093A1 JPWO2014133093A1 (ja) 2017-02-02
JP6490574B2 true JP6490574B2 (ja) 2019-03-27

Family

ID=51428352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015503025A Active JP6490574B2 (ja) 2013-02-28 2014-02-27 不溶性フィブリンに対する抗体
JP2018137861A Active JP7012360B2 (ja) 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018137861A Active JP7012360B2 (ja) 2013-02-28 2018-07-23 不溶性フィブリンに対する抗体

Country Status (5)

Country Link
US (1) US9429584B2 (enExample)
EP (2) EP3339327A3 (enExample)
JP (2) JP6490574B2 (enExample)
ES (1) ES2673583T3 (enExample)
WO (1) WO2014133093A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016167227A1 (ja) * 2015-04-13 2016-10-20 国立研究開発法人国立がん研究センター 不溶性フィブリンに対する抗体
TWI603980B (zh) 2015-09-01 2017-11-01 免疫功坊股份有限公司 用以治療病理性血栓的聯合接合物構型藥物
WO2018092885A1 (ja) 2016-11-18 2018-05-24 アステラス製薬株式会社 新規な抗ヒトMUC1抗体Fabフラグメント
RS67792B1 (sr) * 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
US11311626B2 (en) 2017-05-02 2022-04-26 National Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
TWI795415B (zh) * 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類CEACAM5抗體Fab片段
CN110997013B (zh) 2017-07-24 2022-09-20 瑞泽恩制药公司 抗cd8抗体和其用途
US12202908B2 (en) 2018-05-17 2025-01-21 Astellas Pharma Inc. Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
JP2022501428A (ja) * 2018-09-17 2022-01-06 アイカーン スクール オブ メディスン アット マウント シナイ 抗lilrb2抗体およびその使用の方法
MX2021004146A (es) 2018-10-10 2021-06-08 Astellas Pharma Inc Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado.
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2021163989A1 (en) 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anti-baff receptor antibodies and uses thereof
CN115552012A (zh) * 2020-03-31 2022-12-30 国立研究开发法人国立癌症研究中心 适于溶解纤维蛋白凝块的融合蛋白及包含该融合蛋白的药物组合物
US12600797B2 (en) * 2020-03-31 2026-04-14 Rin Institute Inc. Fibrin-binding antibody and pharmaceutical composition containing antibody
EP3916009B1 (en) * 2020-05-26 2023-06-28 Sartorius Lab Instruments GmbH & Co. KG Recombinant proteins based on fibrinogen
WO2023195535A1 (ja) 2022-04-08 2023-10-12 株式会社凜研究所 フィブリンに結合する抗体および当該抗体を含むフィブリン溶解性タンパク質および当該タンパク質を含む医薬製剤
CN118240085B (zh) * 2022-10-08 2025-05-09 东莞市朋志生物科技有限公司 抗纤维蛋白降解产物抗体、检测纤维蛋白降解产物的试剂和试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4916070A (en) 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
JPH11206387A (ja) 1991-08-28 1999-08-03 Genpharm Internatl Inc 異種免疫グロブリンを作る方法及びそのためのトランスジェニックマウス
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
JPH11505107A (ja) 1995-04-28 1999-05-18 アブジェニックス インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
JPH08301900A (ja) 1995-04-28 1996-11-19 Shima Kenkyusho:Kk 可溶性フィブリン複合体に対するモノクローナル抗体
JPH09104700A (ja) 1995-10-09 1997-04-22 Bio Rinkusu Kk 抗ヒト可溶性フィブリン抗体及びそれを用いた免疫学的測定法
JP2001354700A (ja) 2000-06-12 2001-12-25 Bio Links Kk モノクロ−ナル抗体及びヒトフィブリン分解産物の測定方法
ES2376454T3 (es) 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
CN102206276B (zh) 2001-06-26 2013-07-17 艾根生物医学有限公司 血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体
JP5222521B2 (ja) 2004-12-28 2013-06-26 積水メディカル株式会社 抗ヒト可溶性フィブリンモノクローナル抗体の製造方法
JP4088328B2 (ja) 2004-12-28 2008-05-21 第一化学薬品株式会社 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
EP2514824A3 (en) * 2006-03-03 2013-01-23 Amorfix Life Sciences Ltd. Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
WO2008096760A1 (ja) 2007-02-05 2008-08-14 Osaka University 新規ヘキサトリエン-β-カルボニル化合物
EP2359852A4 (en) 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
JP5805363B2 (ja) * 2009-06-26 2015-11-04 和興フィルタテクノロジー株式会社 可溶性凝集体、免疫寛容誘導剤及びその製造方法
JP2012000072A (ja) * 2010-06-18 2012-01-05 Japan Health Science Foundation 新規な抗フィブリン抗体
AR086250A1 (es) * 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo

Also Published As

Publication number Publication date
ES2673583T3 (es) 2018-06-22
EP3339327A3 (en) 2018-09-19
EP2963059A1 (en) 2016-01-06
EP2963059A4 (en) 2017-03-22
JP2018193386A (ja) 2018-12-06
WO2014133093A1 (ja) 2014-09-04
JP7012360B2 (ja) 2022-02-14
JPWO2014133093A1 (ja) 2017-02-02
US9429584B2 (en) 2016-08-30
EP2963059B1 (en) 2018-04-04
US20160011217A1 (en) 2016-01-14
EP3339327A2 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
JP7012360B2 (ja) 不溶性フィブリンに対する抗体
CA2646329C (en) Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US8101713B2 (en) Prostate cancer diagnosis and treatment
BR112012029281B1 (pt) anticorpo contra trop-2 humano, anticorpo monoclonal contra trop-2 humano, fragmento de anticorpo derivado de anticorpo, hibridoma, conjugado, composição farmacêutica, uso de composição farmacêutica, método para detectar um tumor e kit para tratar, diagnosticar ou detectar um tumor
MX2011004684A (es) Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
JP2013522167A (ja) uPAR結合剤及びその使用方法
ES2615387T3 (es) Anticuerpos contra el antígeno 1 asociado al riñón y fragmentos de unión al antígeno de estos
US6835549B2 (en) Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma
WO2017097990A1 (en) Antibodies for treatment and diagnosis of inflammatory bowel disease
WO2025040093A1 (zh) 靶向gpc3的分子探针以及用途
WO2011158973A1 (ja) 新規な抗フィブリン抗体
TW201842938A (zh) 可藉由胞漿素切斷之抗不溶性纖維蛋白抗體與藥物之複合體
WO2011090166A1 (ja) 食道癌マーカー
KR20140067047A (ko) 대장암 또는 식도암의 검출용 마커 및 검사 방법
WO2016167227A1 (ja) 不溶性フィブリンに対する抗体
KR20130135869A (ko) 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제
KR101380057B1 (ko) 췌장암의 진단제 및 치료제
US20140178906A1 (en) Monoclonal antibodies against pcbp-1 antigens, and uses therefor
KR20260051040A (ko) Ror1에 대한 항체 및 이의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190227

R150 Certificate of patent or registration of utility model

Ref document number: 6490574

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350